BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15737878)

  • 1. Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease.
    Tallman MS; Zakarija A
    Transfus Apher Sci; 2005 Feb; 32(1):99-103. PubMed ID: 15737878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoconjugates in the management of hairy cell leukemia.
    Kreitman RJ; Pastan I
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
    Else M; Dearden CE; Catovsky D
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):217-29. PubMed ID: 26614900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Moxetumomab pasudotox-Third line in Hairy cell leukemia].
    Montes L; Herbaux C
    Bull Cancer; 2021 Dec; 108(12):1073-1074. PubMed ID: 34776118
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in the treatment of hairy-cell leukaemia.
    Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
    Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotoxins in the treatment of refractory hairy cell leukemia.
    Kreitman RJ; Pastan I
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
    Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
    Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
    D'Orazio AI
    Clin Lymphoma; 2001 Jun; 2(1):11-7. PubMed ID: 11712543
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
    Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
    Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
    Saven A; Burian C; Koziol JA; Piro LD
    Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. My treatment approach to hairy cell leukemia.
    Naik RR; Saven A
    Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
    Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to the patient after relapse of hairy cell leukemia.
    Kreitman RJ; Fitzgerald DJ; Pastan I
    Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological management of hairy cell leukemia.
    Ramos Perez J; Ravandi-Kashani F
    Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy for hairy cell leukemia.
    Ravandi F
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):230-5. PubMed ID: 26614901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.
    Gerrie AS; Zypchen LN; Connors JM
    Blood; 2012 Mar; 119(9):1988-91. PubMed ID: 22223825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.